Henry Ford Cancer Institute Senior Leadership

The Henry Ford Cancer Institute is led by an esteemed group of physicians, clinicians, researchers, and advisors, each of whom do their part to ensure excellence in cancer care, education, and research.

Steven Kalkanis MDSteven N. Kalkanis, M.D.
Medical Director of Henry Ford Cancer Institute

Dr. Kalkanis is professor and chair of the Department of Neurosurgery, and co-director of the Neuroscience Institute at Henry Ford Health System in Detroit, Michigan, where he also serves as Medical Director of the Henry Ford Cancer Institute (HFCI). The newly formed HFCI, under the leadership of Dr. Kalkanis, has grown to a $1.2 billion enterprise with 1425 employees treating more than 8,000 new cancer patients and over 100,000 patient visits each year across all five Henry Ford sites – one of the largest cancer centers in the country.

Dr. Kalkanis joined Henry Ford in 2004 after completing his neurosurgical training at Massachusetts General Hospital. He graduated with highest honors from Harvard University, where he was awarded the John Harvard Scholarship, and then Harvard Medical School, where he served as class marshal and received the Linnane Prize for highest academic achievement.

In 2009, Dr. Kalkanis led a multidisciplinary team of experts to publish the first and largest set of guidelines to date in organized neurosurgery on the clinical treatment pathways for metastatic brain tumors. Since that time, he has chaired the guidelines efforts of the Joint Section on Tumors and was the founding chair of the Congress of Neurological Surgeons (CNS) Guidelines Committee. Dr. Kalkanis also serves as a vice-chair on the Joint Guidelines Committee and has helped to spearhead ten separate clinical practice guidelines in a myriad of neurosurgical topics.

Dr. Kalkanis has served on the Executive Committee of the Congress of Neurological Surgeons, the largest neurosurgical association in the world, since 2009, and was recently elected as Chair for the Section on Tumors. He also is currently the Secretary of the CNS. In 2018, Dr. Kalkanis was chosen to receive one of the profession’s highest honors in being named a Director of the American Board of Neurological Surgery.

With the goal of refining future personalized medicine treatment protocols, and as the Mark Rosenblum Endowed Chair in Neurosurgery, Dr. Kalkanis runs a funded translational research laboratory investigating the molecular genetic differences between short-and long-term glioma survivors. Specializing in brain tumor surgery, he has been involved in numerous clinical trials for brain tumors and has authored over 125 peer reviewed publications.

Spencer HooverSpencer Hoover
VP and executive Director of Henry Ford Cancer Institute

Spencer Hoover, a decorated U.S. Army veteran, joined Henry Ford Health System in 2015. He serves as vice president and executive director of the health system’s Henry Ford Cancer Institute and cancer care services.

Reporting to Henry Ford Health System President and Chief Operating Officer Bob Riney, and Henry Ford Medical Group Chief Executive Officer William Conway, M.D., Hoover plays a prominent role in establishing and accomplishing business development goals; service line growth, quality, and integration; external affiliation and partnership development; marketing; and philanthropy.

In collaboration with the Henry Ford Cancer Institute Medical Director Steven N. Kalkanis, M.D., Spencer Hoover is tasked with developing an infrastructure that supports the development of strategic and tactical plans to achieve the financial, clinical, and quality goals established by the health system’s executive leadership team.

Hoover has played an integral role in the development and operational design of the Cancer Institute’s Precision Medicine Program. This effort, in collaboration with a multidisciplinary team of Henry Ford specialists, resulted in the Cancer Institute joining Vice President Joe Biden’s Cancer Moonshot Initiative last summer.

During four years of service as an infantry soldier in the Army’s 82nd Airborne Division, Hoover was awarded six medals, four special qualification badges and three combat patches. He served combat missions in Iraq and Afghanistan.

Hematology/Oncology

  • Hari Menon
  • Deanne Miller

Bone Marrow Transplant

  • Dr. Nalini Janakiraman
  • Hari Menon

Radiation Oncology

  • Dr. Ben Movsas
  • Hari Menon

Downriver Market

  • Dr. Haythem Ali
  • Frank Torti

Northeast Market

  • Dr. Dawn Severson
  • Chris Bissell

Northwest Market

  • Dr. Salim Siddiqui
  • Miles Schermerhorn

West Market

  • Dr. Malcolm Trimble
  • Karen Yacobucci

HFCI Partnering Physician Criteria

  • Dr. Salim Siddiqui
  • Karen Yacobucci

HFCI Screening Standardization

  • Karen Yacobucci

HFCI Cancer Care Pathways

  • Dr. David Kwon
  • Madelyn Van Tassel

HR Model Management

  • Madelyn Van Tassel

HFCI Quality & Finance Committee

  • Dr. Steven Chang
  • Frank Torti
  • Jim Bongiorno

HFCI Research Committee

  • Dr. Margot LaPointe
  • Dr. Ben Rybicki

Clinical Trials Office

  • Dr. Ding Wang
  • Dr. Igor Rybkin
  • Tiffany Pearce

Precision Medicine Program

  • Nadia Haque
  • Louisa Laidlaw
  • Dr. Dhan Chitale
  • Dr. Igor Rybkin
  • Dr. Ding Wang

Enterprise Data Warehouse

  • Pravin Sapre
  • Nadia Haque
  • Dr. Mark Tuthill

Laboratory- Cancer, Research, PMP Integration

  • Dr. Mark Tuthill
  • Ewelina Churchill

HFCI Cancer Registry

  • Chris Bissell
  • Lisa Landvogt

Telemedicine/Virtual Care

  • Miles Schermerhorn

Oral Chemotherapy Management Program

  • Dr. Igor Rybkin
  • Matt Iwanski

HFCI Development

  • Jennifer Harmon

Supportive Oncology Services

  • Dr. Michael Ryan
  • Danielle Nelson

Brigitte Harris Cancer Pavilion

  • Pam Hazel

Referring Physician Outreach

  • Julie Hunter
  • Nicole Leon